DECLARE

Objective

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes (DECLARE).<br> <br> This study is being carried out to see if a new investigational drug called dapagliflozin when added to current treatment for diabetes is effective in reducing cardiovascular events such as heart attack, stroke, and death from heart disease, when compared with placebo (inactive pill having no effect).

Location:

Essentia Health Duluth

Disclosures:

None

For more information about a financial conflict of interest (FCOI), review the Essentia Health FCOI policy.

Last Updated: 06/19/2018

Research Study Categories

  • Adult Studies

Specialty

  • Diabetes
Contact
Clinical Trials at 866-839-4128
or clinicaltrials@eirh.org